ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1946

Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
Abstract Number: 1947

Medication Use in Childhood Sjogren Disease
Abstract Number: 1948

Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Abstract Number: 1949

Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
Abstract Number: 1950

Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
Abstract Number: 1951

Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis
Abstract Number: 1952

Burden of Disease in Refractory Rheumatoid Arthritis
Abstract Number: 1953

Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively
Abstract Number: 1954

Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
Abstract Number: 1955

Predictive Factor of Spontaneous Regression in Methotorexate-associated Lymphoproliferative Disorders with RA Patients
Abstract Number: 1956

Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study
Abstract Number: 1957

Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis
Abstract Number: 1958

The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Abstract Number: 1959

Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database
Abstract Number: 1960

Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].